In the present study, we investigated NRF2 as a potential molecular determinant of the efficacy of Pba-based PDT in human breast carcinoma MDA-MB-231 cells and colon carcinoma HT29 cells. This evidence concerns the gene NFE2L2 and breast carcinoma.